Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Asthma control
See how Relvar can help achieve asthma control
Why molecules matter
Achieving asthma control is influenced by many factors including delivery of inhaled therapies to the lung.
The particle size* range of 1–5 μm is considered optimal for drug delivery to the small airways (<2000 μm).1–6
All particles in Relvar Ellipta* are within the optimal size range for the treatment of asthma.1,2,5–7
There is no evidence that extrafine particles offer any additional clinically relevant benefits compared with standard ICS/LABA particle sizes.7
Relvar's ICS – selected for a longer duration of action vs both budesonide and beclomethasone†8–10
Fluticasone furoate is longer acting and more targeted to the appropriate receptors, compared with both budesonide and beclomethasone (in vitro data)†8–10
Discover Relvar
Footnotes
*Mass median aerodynamic diameter. Lung deposition data does not necessarily predict clinical effects.
†In vitro data: clinical relevance is uncertain.
Abbreviations
AE, adverse event; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist.
Relvar Safety Information11
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Undesirable effects
Very Common: Headache, Nasopharyngitis.
Common: Infections and infestations, Oropharyngeal pain, Sinusitis, Pharyngitis, Rhinitis, Cough, Dysphonia, Abdominal pain, Arthralgia, Back pain, Fractures, Muscle spasms and Pyrexia.
References
- GSK Data on File RF/FFT/0013/15(1);2018.
- Scichilone N, et al. J Asthma Allergy 2013;6:11–21.
- Scheuch G, et al. Adv Drug Del Rev 2006;58:996–1008.
- Gentile DA. Curr Opin Pharmacol 2010;10:260–265.
- Laube BL, et al. ERS Journal 2011;37:1308–1331.
- Zeidler MR, et al. Eur Respir J 2006;27:307–315.
- El Baou C, et al. BMC Pulm Med 2017;17:31.
- Daley-Yates P. Br J Clin Pharmacol 2015;80:372–380.
- Rossios C, et al. Eur J Pharmacol 2011;670:244–251.
- Salter M, et al. Am J Physiol Lung Cell Mol Physiol 2007;293:L660–667.
- Relvar Prescribing Information.
GSK does not recommend, endorse, or accept liability for the 3rd party sites.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني https://moh.gov.om/en/ : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies
PM-RCH-FFV-WCNT-250001 Date of preparation: July 2025
